Mirum Pharmaceuticals reported Phase 3 “victory” in chronic hepatitis delta, building momentum after its acquisition of the program. The company said more than half of patients treated with a once-weekly 300 mg regimen achieved the study’s primary “response” measures, strengthening Mirum’s path toward commercial positioning. Mirum’s update comes as it competes in a space that has seen renewed attention from multiple developers seeking differentiated regimens and durability of response. The company’s report reinforces that its manufacturing and regulatory strategy can support a near-term pathway to a new branded offering. While shares reacted unevenly in the report, the clinical readout increases the likelihood that Mirum can convert clinical differentiation into a clearer FDA filing timetable.